January 2025 Transforming tomorrows, today.

Cautionary Note

Please note that this presentation regarding Insightec, including any accompanying oral presentation, is designed to focus on the company's progress and achievements, not all material developments; discusses uses of the company's products or technology that are not yet proven or approved; omits mention of significant risks; and contains summary information that is necessarily incomplete. Accordingly, it should not be given undue reliance. It also contains forward-looking statements regarding, among other things, plans, expectations, and future events. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec as of the date of the statement. All written or oral forward-looking statements attributable to Insightec are qualified by this caution. Insightec does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec's expectations.

This presentation also contains statistical data, estimates and forecasts that are based on independent industry publications or other publicly available information, as well as other information based on our internal sources. This information involves many assumptions and limitations, and you are cautioned not to give undue weight to such information. We have not independently verified the accuracy or completeness of the information contained in the industry publications and other publicly available information. Accordingly, we make no representations as to the accuracy or completeness of that information nor do we undertake to update such information after the date of this presentation.

"Exablate," and "Exablate Neuro," as well as the "Insightec" logo, whether standing alone or in connection with the word "Insightec", are protected trademarks of Insightec.

INSIGHTEC-Focused Ultrasound for Movement Disorders

OUR MISSION

To transform lives by delivering the therapeutic power of acoustic energy .

TRANSFORMING NEUROSURGERY

TODAY

OUR TECHNOLOGY | HOW IT WORKS

OUR TECHNOLOGY | ADVANTAGES

INCISIONLESS NEUROSURGERY PLATFORM

Insightec's Magnetic Resonance guided Focused Ultrasound

Overview*

Safely transverse the skull with no incisions and therefore no risk of infection
Precise sub-millimetric control
Real-time assessment of side effects and benefit*
Precise adjustments before final ablation
Immediate outcomes
Quick recovery-Outpatient procedure

OUR TECHNOLOGY | ESSENTIAL TREMOR PATIENT EXPERIENCE

PERSONALIZED PRECISION Hemispheric Ultrasound Array + Thermometry

PATIENT RESULTS* Before + After Exablate Neuro

MOVEMENT DISORDERS | GLOBAL COMMERCIAL PROCEDURES

PROCEDURES

Commercial treatments to date*

*Data on file at Insightec.

MOVEMENT DISORDERS | COMMERCIAL INSTALLED BASE

MOVEMENT DISORDERS | AN UNDERSERVED POPULATION

MOVEMENT DISORDERS | LARGE, UNTAPPED MARKET

*Based on 2023 MedScout claims data on patient population and DBS volumes combined with Insightec treatment data on file (ET & PD)

**MOVEMENT DISORDERS* |** FDA STATUS

*FUS treats some of the motor symptoms of ET and PD. For a full list of indications and warnings please refer to the FDA website: Pre-Market Approval (PMA) P150038 or Indications for Use Summary

ESSENTIAL TREMOR | PUBLICATIONS AND SOCIETY SUPPORT

43 peer reviewed publications on focused ultrasound and movement disorders ¹⁴

ESSENTIAL TREMOR | CLINICAL EVIDENCE

73.8%

Tremor improvement at five-year follow-up.¹

44.5% Sustained improvement in QoL at 5 years. 2

CRST Part A: Tremor Improvement

For complete safety and indication information please visit our website Safety, Precautions, and Warning Information | Insightec

^1. Pre-Market Approval (PMA) P150038/S015. Based on data from 76-patients enrolled in randomized controlled trial.

^2. CRST Part C: Activities of Daily Living/Quality of Life functional , PMA P1150038/S015

ESSENTIAL TREMOR | ESTABLISHED REIMBURSEMENT

Billable Event Description	Stage	CPT Code	APC Code	2025 CMS Reimbursement
Pre-Op Brain MRI w/o Contrast*	Pre-Op	70557	5524	\$508
Pre-Op CT MRI w/o Contrast*	Pre-Op	70450	5525	\$106
3D Treatment Planning	Intra-op	77295	5613	\$1,368
QA Machine Consult	Intra-op	77370	5611	\$133
Teletherapy isodose plan; complex includes basic dosimetry calculation(s)	Intra-op	77370	5612	\$366
Focused Ultrasound Delivery for Essential Tremor*	Intra-op	0398T	5463	\$12,470
Post-Op MRI w/o contrast (treatment effect)*	Post-Op	70557	5524	\$508
			Total	\$15,459*

CMS Hospital Outpatient Prospective Payments for fiscal 2025

National Private Payers: US Treatment Sites

Treatment Center

PARTNERSHIP

Medicare coverage in all 50 States
Favorable coverage by majority of private payors in the US
CPT 1 code established for routine physician payment in 2025

*Billable events covered by Medicare. Total stack typically covered by private payors.

ESSENTIAL TREMOR | U.S. ADDRESSABLE MARKET

ESSENTIAL TREMOR | EXPANDING PATIENT TREATMENT

U.S. Essential Tremor Patients

		Source: Medscout, Insightec Data
--	--	----------------------------------	--

Market	ET Patients1	Target Patient Market2	DBS Adoption2	Exablate Adoption3	Exablate Adoption if all Severe3
Houston	6,822	1,624	1.6%	7%	24%
Oklahoma City	2,600	1,105	1.0%	7%	23%
Charlotte	3,820	1,910	0.9%	6%	21%
Durham	4,488	2,244	0.6%	5%	17%
Portland, OR	7,292	3,099	0.5%	4%	15%
Boston	13,290	5,648	0.4%	2%	8%
New York	23,398	9,944	0.2%	2%	8%

Diagnosed ET patients living in market. Medscout 2023 data accessed Jan 2025
Estimated at 50% of diagnosed population with SDR <0.4…out of eligible U.S. patient population of 210,000
2024 Exablate adoption out of 2023 MedScout target patient market
2024 Exablate adoption out of 2023 MedScout target patient market adjusted to severe disease population

PARKINSON'S DISEASE

Meet Kimberly Key Patient Details

Age: 48 year-old
Symptoms: dystonia, numbness, tremors stiffness, loss of muscle control
Medication: levodopa with serious side effects
Procedure Time: two hours
Recovery time: running one day after treatment
Side effects: mild headaches resolved days after treatment

PARKINSON'S DISEASE | THROUGH PROGRESSION

ROBUST BUSINESS MODEL

Exablate Prime System: \$2.5M

(Includes first year warranty)

Ablation Programs:

Treatment Kit: \$3,300 or \$4,300 per procedure
Annual Service Contract: \$205,000 per system

EXABLATE | PROFITABLE CUSTOMER ECONOMICS

2024 Marginal Profit Per Procedure by

▪ Does not require dedicated MRI

Most customers utilize MRI a single day per week (diagnostic MRI).
Mature commercial customers perform 3-5 procedures per day; most profitable MRI day
ROI driven by utilization
With 7-year amortization, customers typically break-even at 40-50 annual procedures
Exablate Prime enables incremental procedures per day

*Reimbursement from slide 16, U.S. list prices, 2 procedures per week and 7-year system amortization **Excludes first-year warranty at equivalent of annual service cost

Modeled based on actual price for system and service, \$3,300 kit price, 7-year system depreciation and 2024 procedures * Excludes customers in initial 12-month ramp-up following installation